Researchers are testing a new ‘gut reset’ procedure to help patients avoid GLP-1 weight loss rebound
A new “gut reset” procedure is drawing attention as a possible fix for one of the most stubborn problems in weight medicine: the weight that returns once people quit drugs like Ozempic.
Early trial results suggest a single outpatient treatment could help patients hold onto most of what they lost after stopping.
Researchers are framing it as a promising off-ramp from GLP-1 weight loss drugs, and the biology behind it is unusual enough to be worth understanding. Here’s everything to know about the procedure (what it is, why the ozempic rebound happens, what the data shows and where things stand now).
What is the DMR “gut reset” procedure?
Duodenal mucosal resurfacing, or DMR, is an experimental outpatient procedure informally known as a “gut reset.”
A thin tube is threaded through the GI tract to the duodenum (the top portion of the small intestine, just below the stomach). Heat is then delivered through the tube to burn away the unhealthy inner lining.
The aim is to “reset” the metabolism to match a person’s new, lower weight, so they can maintain their ozempic weight loss without staying on medication.
Why the Ozempic rebound happens
Most people don’t stay on GLP-1 drugs long-term. A 2024 JAMA Viewpoint estimated that 50 to 75% of users stop within 12 months, often because of cost, side effects or reluctance to medicate indefinitely.
When they stop, the weight tends to return fast. A 2026 University of Cambridge meta-analysis found patients regain an average of 60% of their lost weight within a year.
The regain is projected to plateau around 75% of the original loss, meaning most people keep off about 25% of what they lost.
How the gut reset procedure targets GLP-1 weight loss
GLP-1 weight loss drugs work by mimicking the GLP-1 hormone, which regulates insulin and blood sugar, reduces appetite and slows digestion.
That hormone is produced in the duodenum, the exact spot DMR resurfaces. By targeting the lining where the signal originates, the procedure attempts to recreate some of the drug’s effect without the drug.
What the new DMR study found
The trial was led by Dr. Shelby Sullivan, director of the Endoscopic Bariatric and Metabolic Program at Dartmouth Health Weight Center in Lebanon, New Hampshire.
Researchers recruited 45 participants who had lost at least 15% of their body weight (about 40 pounds on average) on tirzepatide (Mounjaro/Zepbound) but were stopping the drug. 29 of them got the real procedure; the rest received a sham version, and according to U.S. News, participants couldn’t tell which one they’d had.
The findings, six months after stopping tirzepatide:
- The sham group regained 40% more weight than those who got the real procedure.
- Patients with more of their gut resurfaced regained only about 7 pounds, keeping off more than 80% of their lost weight.
- The control group regained roughly twice as much.
- The gap between the groups widened from one month to six.
Sullivan noted the benefit appeared to grow over time rather than fade, and behaved like a drug in its dose response (a sign, she said, that the team is targeting the right biology).
What’s next for the gut reset procedure
The first trial was small, and researchers plan to keep tracking participants’ weight. A larger clinical trial with more than 300 participants is already underway (fully enrolled and randomized) with early results expected later this year.
This article was created by content specialists using various tools, including AI.
